Zydus Lifesciences Q1 Financial Highlights

Zydus Lifesciences announced a 3% year-on-year increase in its consolidated net profit, reaching Rs 1,467 crore for the first quarter ended June 30, 2025. This growth is attributed to robust performance in both domestic and international markets.

Revenue Growth and Business Performance

The company's revenue from operations rose to Rs 6,574 crore, compared to Rs 6,207 crore in the same period last year. Sharvil Patel, MD of Zydus Lifesciences, highlighted the company's disciplined execution and optimism for future innovations.

Segment-wise Growth

Domestic business revenue saw a 6% increase, while the formulations business grew by 8%. The consumer wellness and US formulations businesses also reported positive growth.

Shares of Zydus Lifesciences ended 0.27% higher at Rs 958.05 on BSE.